Wu, Feng-Ping Yang, Ying Li, Mei Liu, Yi-Xin Li, Ya-Ping Wang, Wen-Jun Shi, Juan-Juan Zhang, Xin Jia, Xiao-Li Dang, Shuang-Suo
...
Published in
World Journal of Gastroenterology
BACKGROUND Nucleos(t)ide analog (NA) has shown limited effectiveness against hepatitis B surface antigen (HBsAg) clearance in chronic hepatitis B (CHB) patients. AIM To evaluate the efficacy and safety of add-on peginterferon α-2a (peg-IFN α-2a) to an ongoing NA regimen in CHB patients. METHODS In this observational study, 195 CHB patients with HBs...
Lin, Su Ye, Qiaoxia Wang, Mingfang Wu, Yinlian Weng, Zhiyuan Zhu, Yueyong
Published in
Gastroenterology research
The aim of this study was to assess the efficacy and safety of peginterferon α-2a (pegIFN) and nucleos(t)ide analogues (NA) treatments in patients with hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B (CHB) with mild acute exacerbation (AE). Treatment-naive HBeAg-positive CHB patients with AE who received pegIFN or NA (entecavir (E...
Lim, Kieron B L Sima, Hamid R Fiel, M Isabel Khaitova, Viktoriya Doucette, John T Chernyiak, Maria Ahmad, Jawad Bach, Nancy Chang, Charissa Grewal, Priya
...
Published in
World journal of gastroenterology
To describe our experience using a low-accelerating-dose regimen (LADR) with pegylated interferon alpha-2a and ribavirin in treatment of hepatitis C virus (HCV) recurrence. From 2003, a protocolized LADR strategy was employed to treat liver transplant (LT) recipients with recurrent HCV at our institution. Medical records of 182 adult patients with ...
Sakatani, Akihiko Doi, Yoshinori Matsuda, Takaaki Sasai, Yasutaka Nishida, Naohiro Sakamoto, Megumi Uenoyama, Naoto Matsumoto, Yoshiya Kinoshita, Kazuo
Published in
World journal of gastroenterology
Peginterferon is a key drug used to treat chronic viral hepatitis that is known for causing various side effects. Side effects occurring immediately after administration include headache, nausea, and influenza-like symptoms, such as fever and joint pain. However, reports of anaphylactic shock are extremely rare. Here we report a patient with protra...
Ogasawara, Sadahisa Chiba, Tetsuhiro Ooka, Yoshihiko Kanogawa, Naoya Motoyama, Tenyu Suzuki, Eiichiro Tawada, Akinobu Kanai, Fumihiko Yokosuka, and Osamu
Published in
Investigational New Drugs
Background Several pilot studies have demonstrated the effectiveness of combination therapy with pyrimidine fluoride and interferon for advanced hepatocellular carcinoma.This study aimed to determine the recommended dose of capecitabine combined with peginterferon α-2a (Phase I) and evaluate its safety and efficacy for sorafenib-refractory advanced...
García-Samaniego, Javier Romero, Miriam Granados, Rafael Alemán, Remedios Jorge Juan, Miguel Suárez, Dolores Pérez, Ramón Castellano, Gregorio González-Portela, Carlos
Published in
World journal of gastroenterology
CHC patients treated with peginterferon-α-2a/ribavirin in clinical practice show high EVR. Older age, genotype 1/4, and high GGT were associated with lack of EVR.
Miyase, Shiho Haraoka, Katsuki Ouchida, Yoshihiro Morishita, Yuko Fujiyama, Shigetoshi
Published in
Journal of Gastroenterology
BackgroundPegylated interferon (PegIFN) plus ribavirin is the standard therapy for patients with chronic hepatitis C genotype 1. Although several randomized clinical trials have compared PegIFNα-2a with PegIFNα-2b, these 2 regimens have not been directly compared in Asian patients. We, therefore, compared the safety and antiviral efficacy of these ...
Derbala, Moutaz Shebl, Fatma-M Rashid, Awad Amer, Aliaa Bener, Abdulbari
Published in
World journal of gastroenterology
HCV affected the development of microalbuminuria independent of diabetes or cryoglobulinemia. Combination therapy of pegylated interferon-ribavirin had a positive effect in reducing microalbuminuria.
